Decline in no-authorized generic deals, FTC reports

Fewer patent settlements involve agreements by branded drug companies to stay out of the generic marketplace, according to a Federal Trade Commission report.

Only 21 agreements from Oct. 1, 2013, to...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch